Skip to main content Skip to footer
American Family Children's Hospital
SHARE TEXT
 


Print Friendly Page

Protocol No. BMTCTN1506

Principal Investigator Hall, Aric

Phase III

Age Group Adult

Scope National

Sponsor Type Externally Peer-Reviewed

Title A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy following Allogeneic Transplant for Patients with FLT3/ITD AML

Applicable Disease Sites Leukemia

Drugs Involved ASP2215 (Gilteritinib); Gilteritinib; placebo

Status Open

Participating Institutions UW Hospital and Clinics